{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:39:49Z","timestamp":1759624789177,"version":"build-2065373602"},"reference-count":6,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.eururo.2022.10.026","type":"journal-article","created":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T10:43:22Z","timestamp":1669459402000},"page":"e45-e46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Uncertainty Persists Regarding the Role of Immunotherapy for Treatment of Metastatic Renal Cell Carcinoma with Favourable Prognosis"],"prefix":"10.1016","volume":"83","author":[{"given":"Chiara","family":"Ciccarese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Iacovelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2022.10.026_b0005","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/cncr.34180","article-title":"Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","volume":"128","author":"Motzer","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2022.10.026_b0010","doi-asserted-by":"crossref","first-page":"102295","DOI":"10.1016\/j.ctrv.2021.102295","article-title":"Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis","volume":"100","author":"Ciccarese","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eururo.2022.10.026_b0015","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","article-title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.eururo.2022.10.026_b0020","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1200\/JCO.2021.39.15_suppl.4500","article-title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): results from 42-month follow-up of KEYNOTE-426","volume":"39","author":"Rini","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2022.10.026_b0025","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"issue":"Suppl 7","key":"10.1016\/j.eururo.2022.10.026_b0030","first-page":"S660","article-title":"Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study","volume":"33","author":"Porta","year":"2022","journal-title":"Ann Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822027828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822027828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:13:09Z","timestamp":1759583589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283822027828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":6,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0302283822027828"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2022.10.026","relation":{},"ISSN":["0302-2838"],"issn-type":[{"type":"print","value":"0302-2838"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uncertainty Persists Regarding the Role of Immunotherapy for Treatment of Metastatic Renal Cell Carcinoma with Favourable Prognosis","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2022.10.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}